EUVIMEDEUVIMED entdecken
Crossref

Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma

Fan Zou, Jialiang Wei, Jialang Zhuang, Yafang Liu, Jizhou Tan, Xianzhang Huang, Ting Liu

Frontiers of Medicine · 2024

DOI: 10.1007/s11684-024-1071-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers of Medicine, 2024. Verfasst von Fan Zou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Cardiovsacular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Science, Guangzhou, 510080, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Glypicans, Liver Neoplasms, Apyrase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD39 serves as a crucial biomarker for neoantigen-specific CD8+ T cells and is associated with antitumor activity and exhaustion. However, the relationship between CD39 expression levels and the function of chimeric antigen receptor T (CAR-T) cells remains controversial. This study aimed to investigate the role of CD39 in the functional performance of CAR-T cells against hepatocellular carcinoma (HCC) and explore the therapeutic potential of CD39 modulators, such as mitochondrial division inhibitor-1 (mdivi-1), or knockdown CD39 through short hairpin RNA. Our findings demonstrated that glypican-3-CAR-T cells with moderate CD39 expression exhibited a strong antitumor activity, while high and low levels of CD39 led to an impaired cellular function. Methods modulating the proportion of CD39 intermediate (CD39int)-phenotype CAR-T cells such as mdivi-1 and CD39 knockdown enhanced and impaired T cell function, respectively. The combination of mdivi-1 and CD39 knockdown in CAR-T cells yielded the highest proportion of infiltrated CD39int CAR-T cells and demonstrated a robust antitumor activity in vivo. In conclusion, this study revealed the crucial role of CD39 in CAR-T cell function, demonstrated the potential therapeutic efficacy of combining mdivi-1 with CD39 knockdown in HCC, and provided a novel treatment strategy for HCC patients in the field of cellular immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularGlypicansLiver NeoplasmsApyraseImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsMiceCell Line, TumorAntigens, CDXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CAR-T cellsCD39antitumor activityhepatocellular carcinomamdivi-1

Substanzen

GlypicansApyraseGPC3 protein, humanReceptors, Chimeric AntigenAntigens, CDENTPD1 protein, human

Autor:innen und Institutionen

  • Guangdong Cardiovsacular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Science, Guangzhou, 510080, China.
  • Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Science), Southern Medical University, Guangzhou, 510080, China.
  • Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
  • School of Food and Drug, Shenzhen Polytechnic University, Shenzhen, 518055, China.
  • Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, 518055, China.
  • The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Department of Laboratory Medicine/State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Me…

Zitieren

APA

Zou, F., Wei, J., Zhuang, J., Liu, Y., Tan, J., Huang, X., & Liu, T. (2024). Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma. Frontiers of Medicine. https://doi.org/10.1007/s11684-024-1071-9

Vancouver

Zou F, Wei J, Zhuang J, Liu Y, Tan J, Huang X, et al. Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma. Frontiers of Medicine. 2024. doi:10.1007/s11684-024-1071-9

BibTeX
@article{Zou2024,
  author = {Zou, Fan and Wei, Jialiang and Zhuang, Jialang and Liu, Yafang and Tan, Jizhou and Huang, Xianzhang and Liu, Ting},
  title = {Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma},
  journal = {Frontiers of Medicine},
  year = {2024},
  doi = {10.1007/s11684-024-1071-9}
}
Kostenlos starten →